Researchers from the U.S., U.K., and Switzerland have developed an artificial intelligence tool that may help identify which men with high-risk, non-metastatic prostate cancer are most likely to benefit from abiraterone — a hormone therapy used to improve survival in advanced cases.
Researchers: AI Test Predicts Which Men Benefit from Prostate Cancer Drug